Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.

@article{Underiner2004DevelopmentOV,
  title={Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.},
  author={Ted L. Underiner and Bruce R Ruggeri and Diane E. Gingrich},
  journal={Current medicinal chemistry},
  year={2004},
  volume={11 6},
  pages={
          731-45
        }
}
Among the known angiogenic growth factors and cytokines implicated in the modulation of normal and pathological angiogenesis, the VEGF family (VEGF-A, VEGF-B, VEGF-C, VEGF-D) and their corresponding receptor tyrosine kinases [VEGFR-1 (Flt-1), VEGFR-2 (Flk-1, KDR), and VEGFR-3 (Flt-4)] play a paramount and indispensable role in regulating the multiple facets of the angiogenic and lymphangiogenic processes, as well as the induction of vascular permeability and inflammation. The receptor VEGFR-2… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 54 CITATIONS, ESTIMATED 58% COVERAGE

Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library

VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2004
2018

CITATION STATISTICS

  • 1 Highly Influenced Citations